Scott A Hammond

6PUBLICATIONS
37CO-AUTHORS
Medical mycologyCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Tumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Jun 16, 2025
In Vivo Labeling Resolves Distinct Temporal, Spatial, and Functional Properties of Tumor Macrophages and Identifies Subset-Specific Effects of PD-L1 Blockade.

Colin Y C Lee, Isaac Dean, Nathan Richoz

|Jan 24, 2024
Tumour-retained activated CCR7+ dendritic cells are heterogeneous and regulate local anti-tumour cytolytic activity.

Colin Y C Lee, Bethany C Kennedy, Nathan Richoz

|Jan 24, 2024
Rapid functional impairment of natural killer cells following tumor entry limits anti-tumor immunity.

Isaac Dean, Colin Y C Lee, Zewen K Tuong

|Dec 22, 2022
Restored Thymic Output after Androgen Blockade Participates in Antitumor Immunity.

Fanny Polesso, Breanna Caruso, Scott A Hammond

|Jun 14, 2022
Safety and Tolerability of MEDI0562, an OX40 Agonist mAb, in Combination with Durvalumab or Tremelimumab in Adult Patients with Advanced Solid Tumors.

Jonathan W Goldman, Sarina A Piha-Paul, Brendan Curti

|Apr 26, 2022
In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue.

Zhi Li, Zewen K Tuong, Isaac Dean

Pageof 1

Frequent Collaborators

4 joint publications

Zhi Li

4 joint publications

Isaac Dean

4 joint publications

David R Withers

4 joint publications

Menna R Clatworthy